COO enters its June 4 earnings with a deceptively striking setup: the stock has shed 17% over the past month to $59.61, pushing the trailing P/E to 12.7x and price-to-book to just 1.3x — yet the Street's average target sits comfortably above $87 on the most recent analyst actions, implying more than 50% upside. The question traders are wrestling with is whether that gap represents genuine value or a falling-knife trap ahead of what has historically been a rough print.
Options positioning is the clearest vote so far, and it is decisively bullish. The put/call ratio has collapsed to 0.26 this week — less than half its 20-day average of 0.47 and just a shade above its 52-week low of 0.20. That dramatic rotation toward calls happened fast: the PCR was running above 0.90 for most of April, spiking past 1.07 during peak tariff anxiety. The reversal over the past two weeks is one of the more extreme sentiment swings in the past year on this name, with call buyers now dominating the tape by roughly 4-to-1. Short positioning is far calmer. SI % of Float ticked up about 3% on the week to 2.7% of the free float — not a high reading, and still well below April's elevated levels when shorts ran closer to 3.1%. Borrowing costs are negligible at 0.55% and availability is loose, meaning new short pressure is not a structural concern here. The borrow market simply is not charged.
The Street's conviction is mixed in a way that frames the tension well. Bulls — Barclays (Overweight, $103 target), Needham (Buy, $101), and Stifel (Buy, $95) — all maintained or raised targets around the last print in March, seeing the contact lens and reproductive healthcare franchises as durable growth drivers. Bears point to Goldman's Sell rating with a $71 target, and Citi's Neutral at $87. The consensus remains a Hold with five analysts there. Notably, all the target actions in the dataset are from March 6 or earlier, meaning the 17% decline since then has outrun the Street's most recent updates — none of those targets has been formally revisited since the slide deepened. The valuation case is arithmetically compelling: EV/EBITDA at 10.4x (per the snapshot multiples), price-to-book down 22.5% over the past 30 days, and a gross margin above 67% in the latest quarter. Yet a P/E of 12.7x on trailing GAAP earnings also reflects how far estimates have been taken down; the RSI14 at 29.6 confirms the stock is technically deeply oversold.
Earnings history is a genuine concern. The two most recent confirmed prints — March 2026 and approximately December 2025 — both produced a roughly 6% decline on day one and a further 6-7% move lower over the subsequent week, for cumulative 5-day losses in the 12-13% range. That reaction pattern is consistent, and it suggests the market has been using COO's earnings as a rerating event rather than a catalyst for relief. Against a stock already down sharply, that history matters more, not less — the next print on June 4 arrives with bulls already positioned through the options market, raising the stakes if the release disappoints again.
On the institutional side, T. Rowe Price and Franklin Resources both added meaningfully in the most recent reporting periods — T. Rowe adding 1.45 million shares and Franklin building by over 2 million — while the largest holders, Vanguard and BlackRock, were broadly stable. That buying from active managers into the weakness is a counterweight to the sell-side caution, though these positions were established before the stock lost another leg.
With COO at a multi-year trough on most valuation measures and options traders aggressively positioned for a bounce, the June 4 print becomes a binary moment: whether the company can deliver guidance that breaks the pattern of successive post-earnings de-ratings, or confirms that the repricing has been fundamental rather than sentiment-driven.
See the live data behind this article on ORTEX.
Open COO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
